BIM
MRSN

Bogle Investment Management’s Mersana Therapeutics MRSN Stock Holding History

Bogle Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-864
Closed -$505K – 282
2020
Q2 		$505K Buy
+864
New +$295K 0.08% 203

Other funds holding MRSN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bogle Investment Management's MRSN Position: Q3 2020 in Review

Bogle Investment Management sold out of Mersana Therapeutics (MRSN) in Q3 2020, closing a stake of 864 shares — an estimated $505K sold.

Bogle Investment Management first reported a position in MRSN in Q2 2020 and held it in 1 quarter. The position peaked at $505K in Q2 2020. 135 funds tracked by Wall St. Rank hold MRSN as of Q3 2020.

  • Bogle Investment Management reported no remaining Mersana Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Bogle Investment Management sold 864 Mersana Therapeutics shares in Q3 2020, an estimated $505K.
  • Bogle Investment Management first reported a position in Mersana Therapeutics in Q2 2020 and held it in 1 quarter.
  • Bogle Investment Management's Mersana Therapeutics position peaked at $505K in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.